Details for Patent: 8,093,297
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,093,297 protect, and when does it expire?
Patent 8,093,297 protects COLCRYS and is included in one NDA.
Summary for Patent: 8,093,297
| Title: | Methods for concomitant administration of colchicine and a second active agent |
| Abstract: | Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. |
| Inventor(s): | Davis; Matthew W. (Erwinna, PA) |
| Assignee: | Mutual Pharmaceutical Company, Inc. (Philadelphia, PA) |
| Application Number: | 13/092,459 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,093,297 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,093,297
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | COLCRYS | colchicine | TABLET;ORAL | 022352-001 | Jul 29, 2009 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
